Biontech & MRNA: Revolution in der Pharmaindustrie

pfizer cfo:

-steigende preise

-nachsteuerprofitabilität von 25%!

Meikel.

neues futter für dein model.

Right now, the market is “clearly not being driven by what I'll call normal market conditions,” D'Amelio explained to Barclays analyst Carter Gould during the virtual event. Instead, it’s “been driven by kind of the pandemic state that we've been in and the needs of governments to really secure doses from the various vaccine suppliers.”

Eventually, Pfizer expects “normal market forces … will start to kick in,” D’Amelio said.

At that point “factors like efficacy, booster ability, clinical utility will basically become very important, and we view that as, quite frankly, a significant opportunity for our vaccine from a demand perspective, from a pricing perspective, given the clinical profile of our vaccine,” D’Amelio told the analyst. Plus, Pfizer believes there will be demand for shots even after the current crisis. Citing variant concerns, Pfizer believes it’s "increasingly likely that an annual revaccination is going to take place” and that those revaccinations will be needed “for the foreseeable future,” the CFO said.

Pfizer has said it expects $15 billion in revenue from the mRNA vaccine this year, and that number could grow as the company negotiates new supply deals. At the Barclays event, D’Amelio said his company expects “return after taxes” of around 25% on the $15 billion figure, or around $3.75 billion. The CFO previously said he expects margins for the vaccine to grow over time.